<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05008588</url>
  </required_header>
  <id_info>
    <org_study_id>CT/STROKE/PSI/2021</org_study_id>
    <nct_id>NCT05008588</nct_id>
  </id_info>
  <brief_title>Combination of Conditioned Medium and Umbilical Cord-Mesenchymal Stem Cells Therapy for Sub-Acute Stroke Infarct</brief_title>
  <official_title>Safety and Efficacy of Combined Conditioned Medium With Umbilical Cord Mesenchymal Stem Cells as A Novel Strategy for Sub-Acute Stroke Infarct</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>PT. Prodia Stem Cell Indonesia</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>PT. Prodia Stem Cell Indonesia</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine the effectiveness of a combination of intranasal&#xD;
      conditioned medium (CM) with intraparenchymal umbilical cord mesenchymal stem cells (UC-MSCs)&#xD;
      transplantation in sub-acute stroke patients to induce neurogenesis. This study has 3 arms&#xD;
      namely CM and UC-MSCs treatment, UC-MSCs treatment only, and control. The investigator&#xD;
      hypothesized that group of CM and UC-MSCs combination is the optimal treatment to induce&#xD;
      neurogenesis in stroke patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline Brain-Derived Neutrophic Factor at one month, 3 months and 6 months after transplantation</measure>
    <time_frame>Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment</time_frame>
    <description>Venous blood collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change from baseline Vascular endothelial growth factor at one month, 3 months and 6 months after transplantation</measure>
    <time_frame>Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment</time_frame>
    <description>Venous blood collection</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change baseline Magnetic Resonance Imaging at 6 month after transplantation</measure>
    <time_frame>Before treatment, 6 month after transplantation</time_frame>
    <description>To observe the brain development (neurogenesis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The National Institute of Health Stroke Scale (NIHSS) Scoring</measure>
    <time_frame>Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment</time_frame>
    <description>The NIH Stroke Scale (NIHSS) is a 15-item scale that is a well-validated and prognostically important measure of stroke-related neurologic deficits in research and clinical care</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>modified Rankin Scale (mRS)</measure>
    <time_frame>Before treatment, one month after treatment, 3 months after treatment, and 6 month after treatment</time_frame>
    <description>The Modified Rankin Scale (mRS) is used to measure the degree of disability in patients who have had a stroke</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Ischemic Stroke</condition>
  <arm_group>
    <arm_group_label>Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intranasal of 160 μl of conditioned medium</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Umbilical cord mesenchymal stem cells treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-parenchymal transplantation of 1-2x10^6 UC-MSCs</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard treatment (control)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Neurologic and Neutrophic Drugs</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Conditioned Medium</intervention_name>
    <description>Intranasal of 160 μl of conditioned medium</description>
    <arm_group_label>Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment</arm_group_label>
    <other_name>Secretome</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Umbilical Cord Mesenchymal Stem Cells</intervention_name>
    <description>Intra-parenchymal transplantation of 1-2x10^6 UC-MSCs</description>
    <arm_group_label>Conditioned medium combined with Umbilical cord mesenchymal stem cells treatment</arm_group_label>
    <arm_group_label>Umbilical cord mesenchymal stem cells treatment</arm_group_label>
    <other_name>Mesenchymal stromal cells</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Neurologic and Neutrophic Drugs</intervention_name>
    <description>Such as clopidogrel, piracetam, citicoline</description>
    <arm_group_label>Standard treatment (control)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female aged 60-80 years diagnosed with ischemic stroke acute or subacute phase&#xD;
&#xD;
          -  The patient has had a CT scan/MRI of the brain to assess ischemic territory&#xD;
&#xD;
          -  The patient must have an NIH Stroke score of 8-20&#xD;
&#xD;
          -  The patient or legal assistant has obtained detailed informed consent regarding the&#xD;
             study protocol and agreeing to participate in the study&#xD;
&#xD;
          -  Patients with The Glasgow Coma Scale (GCS) score &gt; 8&#xD;
&#xD;
          -  Patients with Pt-APTT values within normal limits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with recurrent stroke in the 6 months preceding the episode current stroke&#xD;
&#xD;
          -  CT or MRI images show midline shift and bleeding transformation&#xD;
&#xD;
          -  Participate in similar studies using CM and/or UC-MSC&#xD;
&#xD;
          -  Patients who are immunocompromised and/or who are receiving therapy immunosuppressive&#xD;
&#xD;
          -  Patients who cannot have a CT or MRI examination due to their condition&#xD;
&#xD;
          -  Patients with impaired renal and hepatic function after the onset of ischemic stroke:&#xD;
             Serum Glutamic Oxaloacetic Transaminase (SGOT) and Serum Glutamic Pyruvic Transaminase&#xD;
             (SGPT) &gt; 5x the upper limit of normal values and a significant increase in&#xD;
             urea-creatinine values&#xD;
&#xD;
          -  Patients with a history of malignant tumors or other severe neurologic conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Gatot Soebroto Hospital</name>
      <address>
        <city>Jakarta Pusat</city>
        <state>DKI Jakarta</state>
        <zip>10410</zip>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PT Prodia StemCell Indonesia</name>
      <address>
        <city>Jakarta</city>
        <country>Indonesia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Indonesia</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 1, 2021</study_first_submitted>
  <study_first_submitted_qc>August 9, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2021</study_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ischemic stroke</keyword>
  <keyword>Mesenchymal Stem Cells</keyword>
  <keyword>Conditioned Medium</keyword>
  <keyword>Secretome</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

